Please assess the completion status of the following clinical trial:

Trial Title: Liposome Encapsulated Docetaxel (LE-DT) in Patients With Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* To be included in this study, patients must meet the following criteria:~* Be ≥18 years of age.~* Have advanced (local and/or metastatic) histologically documented cancer considered unresponsive to available conventional modalities or treatments.~* Have an ECOG Performance Status of 0-2.~* Have recovered from acute toxicities of prior treatment:~  * 4 weeks must have elapsed since receiving any investigational agent.~ * 4 weeks must have elapsed since receiving any radiotherapy, or treatment with cytotoxic or biologic agents (≥6 weeks for mitomycin or nitrosoureas). Chronic treatment with non-investigational gonadotropin-releasing hormone analogs or other hormonal or supportive care is permitted.~* \>6 months must have elapsed since receiving a high-dose chemotherapy regimen with stem cell support.~  * 2 weeks must have elapsed since any prior surgery or granulocyte-stimulating growth factor therapy.~ * 12 months must have elapsed since any prior treatment with docetaxel. 5. Be in adequate condition as evidenced by the following clinical laboratory values:~    * Absolute neutrophil count (ANC) ≥1,500/mm3.~   * Platelets ≥100,000/mm3.~   * Hemoglobin ≥9.0 g/dL.~   * Albumin ≥3.0 g/dL.~   * Serum creatinine ≤2.0 mg/dL.~   * Total bilirubin ≤1.5 x institutional upper limit normal (ULN).~   * Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase ≤2.5 x ULN.~      6. Patients (male and female) must be willing to practice an effective method of birth control during the study.~      7. Patient or legal representative must understand the investigational nature of this study and sign an Institutional Review Board (IRB)/Independent Ethics Committee approved written informed consent form prior to treatment.~Exclusion Criteria:~* Patients are excluded from this study for the following:~  1. Active uncontrolled bleeding or bleeding diathesis (e.g., active peptic ulcer disease).~ 2. Any active infection requiring parenteral or oral antibiotic treatment.~ 3. Known infection with human immunodeficiency virus or hepatitis virus.~ 4. Active heart disease including myocardial infarction or congestive heart failure within the previous 6 months, symptomatic coronary artery disease, or arrhythmias currently requiring medication.~ 5. Known or suspected active central nervous system metastasis. (Patients stable 8 weeks after completion of treatment for central nervous system metastasis are eligible.)~ 6. Impending or symptomatic spinal cord compression or carcinomatous meningitis.~ 7. Having pre-existing clinically significant neuropathy (NCI CTCAE Grade ≥ 2 neuromotor or Grade ≥ 2 neurosensory) except for abnormalities due to cancer.~ 8. Having failed a docetaxel-containing regimen.~ 9. Having known non-controllable hypersensitivity to docetaxel or liposomes.~ 10. Currently receiving any other standard or investigational treatment for cancer or any other investigational agent for any indication.~ 11. Requiring immediate palliative treatment of any kind including surgery and/or radiotherapy.~ 12. Female patients who are pregnant or breast-feeding.~ 13. Unwilling or unable to follow protocol requirements.~ 14. Any condition which, in the Investigator's opinion, deems the patient an unsuitable candidate to receive study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LE-DT (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).